Related Experiment Video
Updated: Nov 23, 2025

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Neuropsychiatric Disorders Due to Limbic Encephalitis: Immunologic Aspect
Yu-Chia Kao1, Ming-I Lin2, Wen-Chin Weng3,4
1Department of Pediatrics, E-Da Hospital, Kaohsiung 82445, Taiwan.
Limbic encephalitis (LE) is a rare neurological disorder characterized by neuropsychiatric symptoms. Early diagnosis of LE relies on clinical suspicion and neuronal antibody testing due to limited biomarkers.
Area of Science:
- Neuroimmunology
- Neurology
Background:
- Limbic encephalitis (LE) is a rare neurological condition.
- It presents with acute/subacute neuropsychiatric symptoms, notably memory loss and confusion.
- LE involves antibodies targeting neuronal antigens, disrupting synaptic transmission.
Purpose of the Study:
- To review the molecular and immunologic aspects of limbic encephalitis.
- To enhance awareness of LE's unique characteristics compared to traditional psychiatric disorders.
Main Methods:
- Literature review on molecular and immunologic aspects of LE.
- Analysis of pathogenesis involving antibodies, complement, and T-cells.
- Discussion of diagnostic challenges and paraneoplastic associations.
Main Results:
- LE pathogenesis is complex, involving various immune responses.
- Diagnostic difficulties arise from non-specific CSF markers and imaging findings.
- Paraneoplastic LE necessitates concurrent tumor screening and management.
Conclusions:
- LE is distinct from typical psychiatric illnesses, requiring specialized diagnostic approaches.
- High clinical suspicion and neuronal antibody testing are crucial for early LE diagnosis.
- Integrated treatment involving immunotherapy and tumor management is essential for paraneoplastic LE.
More Related Videos
08:20Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016